| Bioactivity | SR-1903 is an inverse agonist of RORγ and PPARγ (IC50 of ∼100 nM and 209 nM for RORγ and PPARγ, respectively) and a LXR agonist. SR-1903 exhibits anti-inflammatory and anti-diabetic efficacy in collagen-induced arthritis and diet-induced obesity mouse models[1]. |
| Invitro | SR1903 (10 μM) 减弱巨噬细胞中的 LPS (HY-D1056) 信号，抑制 TREM-1 基因表达[1]。SR1903 增加巨噬细胞 RAW264.7 中 LXR 靶基因表达，包括参与巨噬细胞胆固醇流出基因 (ABCG1和SCD) 和脂质代谢基因 (ACACA 和 FASN)[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> SR-1903 相关抗体: |
| In Vivo | SR1903 (20 mg/kg，腹腔注射，一天两次，共 16 天) 在胶原诱发性关节炎 (CIA) 小鼠中改善关节炎症状，防止胸腺细胞的丢失[1]。SR1903 (20 mg/kg，腹腔注射，14 天) 改善饮食诱发性肥胖 (DIO) 小鼠代谢参数，并对肥胖相关的胸腺退化发挥保护作用[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 1414248-06-8 |
| Formula | C27H27F6N3O |
| Molar Mass | 523.51 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Chang MR, et al. Unique Polypharmacology Nuclear Receptor Modulator Blocks Inflammatory Signaling Pathways. ACS Chem Biol. 2019, 14(5):1051-1062. |